Where is the Evidence? A Critical Review of Bias in the Reporting of Clinical Data for Exparel: A Liposomal Bupivacaine FormulationRita M. Hadley1 and Alan P Dine2*
- *Corresponding Author:
- Alan P Dine
BSN, Kimberly Clark Corporation
Pleasant Plain, OH United States
Received date: April 16, 2014; Accepted date: July 26, 2014; Published date: July 28, 2014
Citation: Hadley RM, Dine AP (2014) Where is the Evidence? A Critical Review of Bias in the Reporting of Clinical Data for Exparel: A Liposomal Bupivacaine Formulation. J Clinic Res Bioeth 5:189. doi: 10.4172/2155-9627.1000189
Copyright: © 2014 Hadley RM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Healthcare policies are formed through the dissemination of clinical information or evidence of effectiveness, so that this evidence can reach clinical practice. Manipulation or 'influence' over the data and the subsequent reporting of data can be introduced by anyone involved in a study. This may affect the perception of the evidence that becomes the basis for the determination of best practice in the care for our patients so it must be free of bias. This report illustrates an example of bias introduction into the clinical evidence portfolio of the recently introduced liposomal encapsulated bupivacaine Exparel™. This review then uses this new drug as an example of how bias is introduced into the clinical decision tree and its potential effect on the practice of medicine.